Patent ID: 11925607
Assignee: CELON PHARMA S.A.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 17:
18. A method of treatment of depression, by administration of an inhalable dry powder pharmaceutical composition comprising one or more nominal unit doses of micronized esketamine hydrochloride to the lungs via pulmonary route, wherein said treatment is performed in a dosage regimen that comprises a cycle of multiple sequences of administration by inhalation, said cycle lasting from 10 days to 30 days, wherein each of multiple sequences of administration is performed in a single day, with 2 to 4 day intervals between sequences, and each of said sequences consists of multiple single dose inhalations separated by a break period lasting from 5 to 15 minutes, wherein said micronized esketamine hydrochloride is present in the inhalable dry powder pharmaceutical composition in an amount of 2 mg to 20 mg calculated as a free base per nominal unit dose.